news
LB Pharmaceuticals announces positive schizophrenia trial data
LB Pharmaceuticals announced positive Phase II results for LB-102, showing significant symptom improvement in schizophrenia with a favourable safety profile.
List view / Grid view
Schizophrenia
news
Study reveals how neurotransmitters influence brain gene expression
A new study demonstrates how neurotransmitters affect brain gene expression, offering potential therapeutic insights for circadian rhythm disorders.
article
Organoids: the versatile platform for discovery and regeneration
Anirban Datta, Head of Discovery Biology at Verseon International Corporation, details how recent breakthroughs are bringing once-distant possibilities, such as testing drugs more efficiently and restoring lost organ function through implantation, closer to reality.
news
Five HERV expression signatures linked to psychiatric disorders
This is the first study to demonstrate that a specific set of HERVs expressed in the human brain contribute to disorders like schizophrenia.
article
Documenting the mammalian brain using machine learning
Novel approaches to brain disorder diagnosis and treatment may be developed following a project to form a map of the mouse hippocampus.
news
Incorporating microglia into brain organoids
iPS-cell-derived microglia in brain organoids have enabled scientists to understand early brain development and microglia-associated disease.
news
Placenta’s role in genetic risk of schizophrenia
A recent study led by the Lieber Institute for Brain Development has revealed that over 100 genes associated with the risk of schizophrenia appear to contribute to the development of the illness primarily through their influence on the placenta.
news
Scientists discover multiple pathways of the 5HT2a receptor activated by psychedelics
The new LSD-like compounds activated the 5HT2a receptor, a receptor stimulated by serotonin, without causing hallucinations.
news
Researchers use brain organoids to identify neural abnormalities and test gene therapy tools
Scientists used human brain organoids to reveal how a genetic mutation associated with a profound form of autism disrupts neural development, and gene therapy tools to recover the gene’s function effectively rescued neural structure and function.
news
Scientists explore CA2 neuron mitochondria for memory loss targets
The team will receive $2 million over five years to investigate the CA2 brain region for the development of neurological therapies.
news
Thalamus revealed as key area to target for certain brain disorders
Research shows that cells gather more data inside the thalamus than once believed, potentially changing medicines for brain disorders.
podcasts
Episode 1 – Dr Sri Gopal, Janssen Pharmaceuticals
Listen along to learn more about drug development for schizophrenia from Dr Sri Gopal, Head of Psychiatry R&D for Janssen!
news
Synapse protecting protein could be a target for Alzheimer’s therapies
Researchers suggest the SRPX2 protein, which inhibits complement system-dependent synapse removal could be a target for novel Alzheimer’s and schizophrenia therapies.
news
Ion channel ball-and-chain mechanism imaged after decades of attempts
Scientists have imaged the ball-and-chain mechanism using cryogenic electron microscopy and hope their work could be applied in the design of novel therapeutics.
article
Safer and more affordable medicine for all? How pharmacogenomics may level the playing field
Dr Mike Tocci discusses how pharmacogenomics can revolutionise medical research and improve the efficacy and quality of drugs.